The 370 basis point gross margin improvement over two years suggests the 'Foundations for Growth' initiative is yielding tangible results, likely through manufacturing automation and supply chain optimization. Operating margin expansion to 14.5% in 2026Q2, from 12.2% in 2025Q2, indicates operating leverage is emerging as revenue growth outpaces fixed cost growth. However, the sub-50% gross margin remains below the 60%+ typical of proprietary implant peers, underscoring the high-volume disposable nature of the business. Investors should monitor whether margin gains are sustainable or partly driven by one-time benefits from the recent divestiture.

Despite improving margins, ROIC has been stagnant, ranging from 1.6% to 2.3% over the past two years. This implies that margin gains are being offset by an expanding capital base, likely due to the tuck-in acquisition strategy that has increased goodwill and intangibles. The low ROIC relative to peers like Integer Holdings (5.4%) suggests MMSI's acquisition-driven growth has not yet translated into superior capital efficiency. If the company can integrate recent acquisitions and drive organic growth without proportional capital increases, ROIC could improve, but current trends warrant caution.

Inventory days on hand have climbed from 155 days in 2024Q2 to 162 days in 2026Q2, while DSO and DPO have remained relatively stable. This suggests the company is building inventory, possibly to mitigate supply chain risks or in anticipation of demand, but it also ties up cash. The CCC of 183 days is notably high, reflecting the complexity of managing thousands of SKUs and custom procedural trays. If inventory growth outpaces sales, it could signal obsolescence risk, especially given the fast-changing clinical guidelines. Investors should monitor whether this is a deliberate strategic choice or a sign of operational inefficiency.

The balance sheet has strengthened significantly, with equity expanding 42% over two years, outpacing debt growth. D/EBITDA has improved from 13.93 in 2024Q1 to 8.68 in 2026Q2, indicating that EBITDA growth is reducing leverage even as debt remains near $820M. Interest coverage of 5.23 in 2026Q2, though lower than the 9.21 in 2026Q1, remains adequate. The fortress-like balance sheet provides ample optionality for future acquisitions or share repurchases, but the elevated D/EBITDA relative to peers like Integer (0.80 D/E) suggests MMSI is more leveraged, though still manageable.

The current ratio has consistently remained above 4.0 over the past two years, indicating a substantial liquidity buffer. The quick ratio of 2.79 suggests that even without selling inventory, the company can cover short-term obligations nearly three times over. This liquidity position is particularly reassuring given the inventory-heavy business model and the potential for supply chain disruptions. However, the high current ratio may also indicate inefficient use of cash, as excess liquidity could be deployed for higher-return investments. Nonetheless, in a rising rate environment, this fortress-like liquidity provides significant financial flexibility.